OnKure Therapeutics (NASDAQ:OKUR) Coverage Initiated at Oppenheimer
by Michael Walen · The Markets DailyInvestment analysts at Oppenheimer assumed coverage on shares of OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) in a note issued to investors on Thursday, Marketbeat Ratings reports. The firm set an “outperform” rating and a $35.00 price target on the stock. Oppenheimer’s price objective indicates a potential upside of 90.01% from the stock’s previous close.
OnKure Therapeutics Trading Down 3.1 %
Shares of NASDAQ:OKUR opened at $18.42 on Thursday. The firm has a market cap of $61.52 million, a PE ratio of -1.04 and a beta of 0.21. OnKure Therapeutics has a 52 week low of $9.80 and a 52 week high of $86.70.
OnKure Therapeutics Company Profile
Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.
Featured Articles
- Five stocks we like better than OnKure Therapeutics
- The 3 Best Blue-Chip Stocks to Buy Now
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- Profitably Trade Stocks at 52-Week Highs
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- How to Calculate Return on Investment (ROI)
- 4 Quirky ETFs With Big Potential for Impressive Gains